



1

REINSURANCE **HOT NEWS**

March 17, 2025

Reinsurance Coverage of Three Additional High-Cost Specialty Drugs (BIO)

AHCCCS is pleased to announce the addition of the following drugs to the High-Cost Specialty Drug Reinsurance Program effective October 1, 2024 and include the following:

Bylvay (Odevixibat) is FDA approved to treat Progressive Familial Intrahepatic Cholestasis (PFIC).

Cholbam (cholic acid) is FDA approved treat the following:

- Bile acid synthesis disorders due to single enzyme defects; and
- Adjunctive treatment of peroxisomal disorders including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications from decreased fat-soluble vitamin absorption.

Effective October 1, 2025:

Aucatzyl (obecabtagene autoleucel) is a T cell immunotherapy FDA approved to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

The Request Letter for Catastrophic Reinsurance, on the AHCCCS website, will be updated with the new high-cost specialty drugs in the next few days. If your plan has a member that received Bylvay or Cholbam on or after the effective date of October 1, 2024, you may submit a reinsurance request to AHCCCS Medical Management. The request must be received by AHCCCS Medical Management prior to May 1, 2025.